Resalis Therapeutics Reports Durable, Fat-Selective Weight

Torino, Italy, October 7 – Resalis Therapeutics, a biotechnology company pioneering microRNA-targeted therapies, presented new preclinical results on its lead candidate RES-010, a first-in-class antisense oligonucleotide targeting microRNA-22…